In patients with ALS, glutathione did not significantly change disease progression compared with symptomatic therapies alone.
In plain wordsIn patients with ALS, glutathione did not significantly change disease progression compared with symptomatic therapies alone.
- Peptide
- Glutathione
- Outcome
- No significant changeALS progression
- Study
n = 32
- Comparator
- Symptomatic therapies only
- Outcome group
- Neuroprotection · Nervous system and cognition
- Studied dose
- 600 mg each day · intramuscular · 12 weeksAs given in this study (human).
Source sentences
No significant difference was found in the progression of ALS in the two periods, although a slight slowing of the disease progression rate was found during the period of treatment, probably related to the open design of the study.
5 context sentences(design, population, supporting numbers)
Thirty-two patients affected by definite ALS seen in our institution between August 1993 and July 1994 were admitted to the study.
The effect of GSH was studied in an open, crossover, randomized study.
GSH was given at the dose of 600 mg each day intramuscularly for 12 weeks.
The first group received the drug while the second received only symptomatic therapies for 12 weeks.
After a week of washout, the second group received GSH and the first only symptomatic therapies for 12 weeks.